Enjoy Life Foods plans new Ind. manufacturing facility
CHICAGO — Mondelez International’s Enjoy Life Foods announced Wednesday that it would be opening a new allergy-friendly manufacturing facility in Jeffersonville, Ind. The new facility is expected to open in the second quarter of 2016, and the company’s current Schiller Park, Ill. facility will be closed in the third quarter.
“The growth opportunity afforded by this new facility is an exciting step forward for our brand,” said Scott Mandell, CEO and Founder of Enjoy Life Foods. “We’ve outgrown capacity at our current facility. This new plant will improve overall manufacturing efficiency while providing the space for us to accelerate growth and bring our delicious allergy-friendly and gluten-free snacks to even more people.”
The company said the facility is expected to create between 100 and 150 jobs in the area, with potentially more as it expands.
Sam’s Club kicks off 2016 with free health screening offer for members, non-members
BENTONVILLE, Ark. — For 2016, Americans have three top resolutions in mind — increase savings, increase exercise and lose weight. To help Americans achieve their health goals without straining their wallets, Sam’s Club Pharmacies nationwide will renew its commitment to host several free health screenings throughout the year for both members and non-members, covering a wide range of tests to help discover and manage potential health issues.
These health screenings are free, confidential and available to the public at all Sam’s Club locations with a pharmacy (617 locations). The first screening will take place on Jan. 9 from 11 a.m. to 4 p.m., while supplies last, with a key health indicator review, valued at $150.
“For the last five years, we have been proud to offer these free screenings as an easy and affordable way for the communities we serve to stay on top of their health,” stated Jill Turner-Mitchael, SVP Sam’s Club consumables & health and wellness. “Health and wellness remains a top priority for Sam’s Club and we are constantly striving to find ways to make healthcare more accessible.”
Mylan Pharmaceuticals launches generic Harvoni in India
HERTFORDSHIRE, England – Mylan on Thursday announced that its subsidiary, Mylan Pharmaceuticals has launched generic Harvoni (Ledipasvir 90 mg/Sofosbuvir 400 mg) tablets under the brand name MyHep LVIR in India.
"Mylan recognizes the urgent need to expand access to high quality, affordable Hepatitis C treatment options in India, where roughly 12 million people are infected with the virus," stated Rajiv Malik, Mylan president. "MyHep LVIR is an important addition to our growing Hepato Care segment in India that gives us the opportunity to offer patients the potential to be cured through a transformative and simplified single tablet, once-daily treatment regimen. Moreover, consistent with our commitment to create better health for a better world, we are introducing various educational initiatives in India to raise awareness of the disease and its treatment options."
The Ledipasvir/Sofosbuvir combination is indicated for the treatment of Hepatitis C infection and offers a simplified Hepatitis C treatment regimen that eliminates the need for interferon and ribavirin. The product also is a single-tablet regimen and requires a therapy course of just 12 weeks.
The launch of MyHep LVIR follows the successful launch of generic Sofosbuvir in India under the brand name MyHep in April 2015. In September 2014, Mylan entered into a licensing and technology transfer agreement with Gilead granting Mylan the non-exclusive rights to manufacture and distribute generic Sofosbuvir and Ledipasvir/Sofosbuvir tablets in 101 developing countries, including India.
Mylan also entered into an agreement with Gilead in February 2015 as the exclusive distributor of Gilead's branded Sovaldi (Sofosbuvir 400 mg) and Harvoni tablets in India. Mylan launched Sovaldi in India in May 2015.
Loading Post Please Wait...